<p>IFM Therapeutics Inc was founded in 2015 to transform the
treatment of cancer and inflammatory disease by developing drugs that target
the innate immune system. In September 2017 the company was acquired for its
oncology programmes by Bristol-Myers Squibb, in return for $300 million upfront
and future milestone payments that could exceed $2 billion. At the same
time, the company’s inflammation programmes were spun out into a new entity
that retains the name IFM Therapeutics LLC.</p>